HNWAG
ACET icon

High Net Worth Advisory Group’s Adicet Bio ACET Stock Holding History

High Net Worth Advisory Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31
Closed -$7K – 677
2022
Q2 		$7K Hold
31
– – ﹤0.01% 552
2022
Q1 		$10K Buy
+31
New +$7.13K ﹤0.01% 527

Other funds holding ACET

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

High Net Worth Advisory Group's ACET Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Adicet Bio (ACET) in Q3 2022, closing a stake of 31 shares — an estimated $7K sold.

High Net Worth Advisory Group first reported a position in ACET in Q1 2022 and held it in 2 quarters. The position peaked at $10K in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining Adicet Bio position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 31 Adicet Bio shares in Q3 2022, an estimated $7K.
  • High Net Worth Advisory Group first reported a position in Adicet Bio in Q1 2022 and held it in 2 quarters.
  • High Net Worth Advisory Group's Adicet Bio position peaked at $10K in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.